News | November 25, 2021
Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
It is the world’s first DNA-based Covid vaccine
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The company has to approach the DCGI for approval to commence the trials
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Subscribe To Our Newsletter & Stay Updated
